Back to Ovarian Cancer
NCT00795769
NCT00795769
Who may be able to join
Who might be able to join this trial:
- You are scheduled to receive your own previously collected stem cells back (called an autologous stem cell transplant).
- You speak and understand English.
- Your stem cell infusion is planned to take place at the SCCA outpatient clinic.
Who may not be able to join:
- You have had a previous stem cell transplant using your own cells in the past.
- You do not speak English.
- Your stem cell infusion is planned to take place at the UWMC inpatient unit rather than the outpatient clinic.
- Your stem cells are planned to be thawed and specially washed to remove a preservative chemical called DMSO before being given to you.
- You have had an allergic reaction or a bad reaction to a medication called ondansetron (a common anti-nausea drug) in the past.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 2
Sponsor
Fred Hutchinson Cancer Center
Registry
clinicaltrials_gov
Start date
8 August 2008
Est. completion
9 June 2009
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.